Neuronetics, Inc. revised revenue guidance for the Full Year 2023. For the period, the company expects total revenue to be between $69.0 million and $73.0 million, increasing the bottom end of the range by $1.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.18 USD | -5.22% | -16.48% | -24.83% |
May. 15 | Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents | CI |
May. 14 | William Blair Upgrades Neuronetics to Outperform From Market Perform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.83% | 65.39M | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+2.05% | 65.01B | |
+15.38% | 53.02B | |
+3.96% | 50.45B | |
+8.37% | 44.15B | |
+3.27% | 36.45B |
- Stock Market
- Equities
- STIM Stock
- News Neuronetics, Inc.
- Neuronetics, Inc. Revises Revenue Guidance for the Year Full Year 2023